Kataoka A, Imai H, Inayoshi S, Tsuda T
Third Department of Internal Medicine, Oita Medical University, Japan.
J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1213-6. doi: 10.1136/jnnp.56.11.1213.
The efficacy of intermittent high-dose vitamin C therapy was evaluated in seven patients with HTLV-I-associated myelopathy (HAM). All HAM patients responded well to this therapy without serious side effects. Grade of disability score improved at 9.7 (SD 5.8) months after the therapy from 7.1 (3.3) to 3.6 (2.0) (p < 0.01). Serum immunosuppressive acidic protein was elevated before and decreased after the therapy from 747 (316) to 398 (86) micrograms/ml (p < 0.05), suggesting favourable immunomodulatory action of vitamin C therapy in HAM patients.
对7例人类嗜T淋巴细胞病毒I型相关脊髓病(HAM)患者评估了间歇性大剂量维生素C疗法的疗效。所有HAM患者对该疗法反应良好,且无严重副作用。治疗后9.7(标准差5.8)个月时残疾评分等级从7.1(3.3)改善至3.6(2.0)(p<0.01)。血清免疫抑制酸性蛋白在治疗前升高,治疗后从747(316)微克/毫升降至398(86)微克/毫升(p<0.05),提示维生素C疗法对HAM患者有良好的免疫调节作用。